Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM5 | P41594 | 2/20 | 0.34 |
| ▸ | SRC | P12931 | 1/20 | 0.31 |
| ▸ | GFER | P55789 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | BRD4 | O60885 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16439037 | 0.91 | GRM5 (0.34) | GRM5SRCGFERSMN1; SMN2BRD4 | |
| SCHEMBL17831014 | 0.88 | — | — | |
| SCHEMBL17831013 | 0.83 | SMN1; SMN2 (0.37) | GFERSMN1; SMN2 | |
| SCHEMBL19999697 | 0.83 | SMN1; SMN2 (0.37) | GFERSMN1; SMN2 | |
| SCHEMBL16549064 | 0.77 | LMNA (0.43) | GFERSMN1; SMN2 | |
| SCHEMBL16439035 | 0.77 | ALDH1A1 (0.34) | GRM5 | |
| SCHEMBL16439011 | 0.75 | FLT3 (0.38) | GRM5SMN1; SMN2 | |
| SCHEMBL16439036 | 0.74 | GFER (0.32) | GFERSMN1; SMN2 | |
| SCHEMBL21074282 | 0.74 | ALDH1A1 (0.39) | GRM5GFERSMN1; SMN2 | |
| SCHEMBL19999700 | 0.74 | ALDH1A1 (0.39) | GRM5GFERSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10290817-B2 | Luminescent diaza-monoaza-and benzimidazole metal carbene complexes for use in electronic devices such as OLEDs | UDC IRELAND LIMITED (IE) | 2019-05-14 | — | — | US | disclosed |
| US-20160172606-A1 | LUMINESCENT DIAZA-MONOAZA-AND BENZIMIDAZOLE METAL CARBENE COMPLEXES FOR USE IN ELECTRONIC DEVICES SUCH AS OLEDS | BASF SE (DE) | 2016-06-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160172606-A1 | LUMINESCENT DIAZA-MONOAZA-AND BENZIMIDAZOLE METAL CARBENE COMPLEXES FOR USE IN ELECTRONIC DEVICES SUCH AS OLEDS | OCIAD1, OCIAD2, OXA1L | GRM5 3679/4885SRC 476/4885GFER 1538/4885 |
| US-10290817-B2 | Luminescent diaza-monoaza-and benzimidazole metal carbene complexes for use in electronic devices such as OLEDs | OCIAD1, OCIAD2, OXA1L | GRM5 3679/4885SRC 476/4885GFER 1538/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.